PURPOSE: Hereditary nonpolyposis colon cancer is caused by mutations in DNA mismatch repair genes, predominantly MLH1 and MSH2. Classic MLH1 mutations cause an approximately 20-fold increase in colorectal cancer susceptibility. Recently, we identified a hypomorphic allele, MLH1 D132H, which impairs, but does not completely eliminate the function of MLH1 in tumor suppression. MLH1 D132H confers an approximately fivefold increase in colorectal cancer susceptibility and was first described in a cohort of Israeli colorectal cancer patients, with an estimated allele frequency of 1.3 percent. Because MLH1 D132H has only recently been described, the ethnic distribution of this risk allele is not well understood. This study was undertaken to determine both the frequencies of this risk allele in ethnic groups outside of Israel and whether families harboring this mutation have susceptibility to extracolonic cancers in the hereditary nonpolyposis colon cancer spectrum. METH-ODS: We genotyped two independent cohorts: 629 population-based colorectal cancer patients ascertained from clinics in Orange, Imperial, and San Diego Counties, and 515 endometrial cancer patients ascertained from gynecologic oncology clinics in the Midwestern United States. RE-SULTS: MLH1 D132H was not detected in either study cohort, which together totaled more than 1,100 American colorectal cancer and endometrial cancer patients. CON-CLUSIONS: The MLH1 D132H risk variant has significantly lower allele frequency in American compared with Israeli cancer patients and, alone, is unlikely to explain significant amounts of American sporadic colorectal cancer or uterine cancer susceptibility. Genetic testing for the MLH1 D132H allele exclusively is therefore unlikely to be cost effective for genetic risk assessment in American population-based and clinic-based colorectal cancer and endometrial cancer patients.
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METHODS
A total of 1,134 CRC patients were ascertained through the population-based registries of the Cancer Surveillance Program of Orange County/San Diego Imperial Organization for Cancer Control. These subjects were diagnosed between 1994 and 1996. Detailed information about the population sampling has been previously described. 5 Positive family history was defined as having at least one first-degree relative with CRC, or no first-degree relative with CRC, and at least two maternal or two paternal second-degree relatives with CRC, or at least three maternal or three paternal third-degree relatives. DNA was extracted from blood samples taken from participants. A total of 629 patients had DNA samples available. For endometrial cancer patients, 515 patients were ascertained through Washington University Gynecology Oncology Clinics in Missouri.
4
MLH1 D132H analyses of CRC patient samples were performed in the laboratory of Dr. Steve Lipkin. Allelic discrimination of the CRC sample set was optimized using a custom TaqMan-based SNP Genotyping assay and the ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA 
RESULTS
Clinical characteristics of the CRC cohort from Southern California and the endometrial cancer (EC) patients from Missouri are described in Tables 1 and  2 . For CRC patients, the mean age of diagnosis was 59 years. The vast majority (87.6 percent) of this American CRC subject cohort consisted of non-Hispanic whites. Slightly < three percent (2.7 percent) were of Jewish ethnicity. 5, 6 Approximately one-third (30.7 percent) of cohort has a positive family history of colon or rectal cancer. Almost one-half (48.1 percent) of them were found to have early localized state of disease (Stage 0-2) without involvement of adjacent organs or lymph nodes, but only 7.1 percent of patients had Stage IV disease. Close to two-thirds (65 percent) of the tumors were located in the sigmoid colon or rectum. Complete typing of MSI status for each individual in the cohort is not available at present. From the total of 629 DNA samples analyzed, alleles were determined for 621 patients (98.7 percent). Positive control DNA samples in duplicate from MLH1 D132H heterozygotes were used in each TaqMan assay that was run. In the 621 CRC cases from the Southern California CRC cohort who were assayable, 0 of 621 MLH1 D132H carriers (0 percent) were detected. For the endometrial cancer patients, the mean age of diagnosis was 64.7 years ( Table 2 ). The vast majority of this cohort were non-Hispanic whites and only ∼1.8 percent of the endometrial cancer patient population was of Ashkenazi Jewish ethnicity. Approximately 15 percent of endometrial cancer probands have a first-degree or second-degree relative with colorectal or endometrial cancer. Approximately 80 percent of patients ascertained had endometrioid cancer. Twenty-nine and one-half percent of EC patients have tumors that are MSI-H, and 3 percent MSI-L, similar to our previously described clinic-based population. 3 Of the endometrial tumors that were MSI-H, 71.7 percent lacked MLH1 expression because of epigenetic silencing of MLH1, the most common cause of MSI-H status in this cancer. 3, 7 From the total of 527 DNA samples analyzed, alleles were determined for 515 patients (97.7 percent). Positive control DNA samples in duplicate from MLH1 D132H heterozygotes were used in each pyrosequencing assay that was run. In the 515 EC cases from the Missouri EC cohort who were assayable, 0 of 515 MLH1 D132H carriers (0 percent) were detected.
DISCUSSION
We analyzed the allele frequencies of MLH1 D132H in two cohorts of American cancer patients with HNPCC-related cancers (colorectal and endometrial cancers). Together, these cohorts comprise more than 1,100 patients, most of who were white or mixed European ancestry. In a previous study of populationbased Israeli CRC patients, we detected MLH1 D132H among Ashkenazi Jewish, non-Ashkenazi Jewish, Muslim and Christian Arab, and Druze Christian patients with an estimated allele frequency in CRC patients approximating 1.3 percent. 2 If the allele frequency in the American population were similar, we would expect to find approximately 8 carriers in this 621 American CRC patients, and 7 carriers in the 515 endometrial cancer patients, respectively. However, the MLH1 D132H variant allele was not detected in either of these cohorts. The reasons for this difference in allele frequency could be attributable to differences in either the ethnic makeup, or to a lesser degree, to differences in the clinical characteristics of these two cohorts.
The most striking difference between these cohorts is the low frequency of Jewish patients in the Southern California CRC Cohort analyzed (2.7 percent) 5, 6 and the Missouri Endometrial Cancer cohort (1.8 percent) compared with the previous Molecular Epidemiology of Colorectal Cancer (MECC) study (>80 percent) of population-based Israeli CRC. 2 In the MECC population, Jewish patients comprised 85 percent (Ashkenazi 71 percent, non-Ashkenazi 29 percent). 7, 8 Additionally, distinct clinical characteristics of the two cohorts may account for this allele frequency differences. Approximately 80 percent of the Southern California CRC cohort was diagnosed at aged 50 years or older compared with 94 percent of Israeli population from the MECC Study, and >90 percent of the general population of the United States. 6 Because the average age at which MLH1 D132H carriers developed CRC was 69 compared with 59 in this cohort, the overall younger average age of the American cohort compared with the MECC study population also may contribute to this difference. Only 7.1 percent of this cohort has Stage IV disease compared with 21.9 percent in the general United States population. A considerably higher proportion of familial cases in this Southern California sample (30.7 percent) was noted, because patients with familial risk of CRC makeup approximately 20 percent of all CRC. 8 Although these clinical factors are unlikely to account for the majority of the observed difference in allele frequencies, they perhaps indicate different mechanisms of carcinogenesis in this younger, earlier-staged CRC cohort. For the endometrial cancer patients, it may be notable that there were no endometrial cancers described in the probands or first- Future studies will be required to assess the frequencies of this allele in other ethnic groups. Molecular diagnostic mutation analysis of MLH1 and MSH2 can cost as much as $2,500 per patient. 1 Because of this high cost, individual alleles can be analyzed in specific patient groups to minimize patient expense (such as the panel of Ashkenazi founder mutations for BRCA1 and BRCA2, which reduces patient cost almost tenfold compared with sequencing of the coding region). Our work suggests that genetic testing exclusively for the MLH1 D132H allele is unlikely to be cost effective for genetic risk assessment in American population-based and clinic-based CRC and endometrial cancer patients.
CONCLUSIONS
The MLH1 D132H risk variant has significantly lower allele frequency in American compared with Israeli cancer patients and is unlikely to explain significant amounts of American sporadic CRC and uterine cancer susceptibility. Targeted genetic testing for MLH1 D132H in isolation is unlikely to prove costeffective.
